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WILLIAM W. PARMLEY, MD, FACC
San Francisco. California
Esmolol (ASL-8052) is a new intravenous beta-adren-
ergic blocking agent that has exhibited both cardiac se-
lectivity and an extremely short half-life in animal stud-
ies. To assess its clinical efficacy, 16patients were studied
with a rapid ventricular rate associated with atrial flutter
(n ;;:; 2), atrial fibrillation (n ;;:; 10), atrial tachycardia
(n ;;:; 2) and multifocal atrial tachycardia (n ;;:; 2). Dur-
ing a 30 minute control period of observation, the ven-
tricular rate ranged from 121 to 150 beats/min (mean
133.2 ± 10.6). Using a double blind crossover method,
esmolol was infused intravenously for a maximum of 60
minutes. Infusions of 50, 100, 150, 200, 250 and 300
ltg/kg per min were given in consecutive 5 minute pe-
riods (during the first minute of each period, a loading
dose of 500 ltg/kg was given). Not all patients received
the maximal dose.
A response was defined as conversion to sinus rhythm
or a 20% reduction in ventricular rate. One patient with
atrial fibrillation associated with the Wolff-Parkinson-
White syndrome did not respond. In the remaining IS
The use of an ultrashort-acting beta-adrenergic blocking
agent in the treatment of the critically ill patient was pro-
posed by Zaroslinski et al. (l), who developed such an
agent-esmolol. In their report on the pharmacologic action
of this agent in a canine model, they demonstrated a re-
duction in infarct size as well as beta-adrenergic blocking
activity and cardioselectivity. Such an agent could extend
the usefulness of beta-receptor blocking by virtue of its
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patients, their highest esmolol infusion rate was main-
tained for an additional 30 minutes. This resulted in a
reduction in ventricular rate to a mean of 97.8 ± 12.9
beats/min (range 72 to 119)(p < 0.001). Conversion from
flutter/fibrillation to sinus rhythm occurred in two pa-
tients. During the infusion, six had transient asympto-
matic hypotension that was mild and manageable. After
infusion, ventricular rate and blood pressure returned
rapidly toward control values within 25 minutes in pa-
tients without conversion to sinus rhythm.
It is concluded that intravenous administration of
esmolol is effective in controlling ventricular rate in pa-
tients with a variety of atrial tachyarrhythmias with the
possible exception of the Wolff-Parkinson-White syn-
drome. It may be of use in clinical settings in which a
brief duration of beta-adrenergic blockade is needed,
and may be safe in patients with mild valvular heart
disease, mild chronic obstructive pulmonary disease and
mild congestive heart failure due to a tachyarrhythmia.
ultrashort action and, thus, greatly reduce the dangers of
longer-acting preparations. Intravenous administration of such
an agent would enable the clinician to easily adjust the
degree of beta-adrenergic blockade to match the require-
ments in a rapidly changing clinical setting.
Subsequent phase I studies suggested that esmolol is well
tolerated and effective in reducing the heart rate response
to isoproterenol (2,3). However, the safety and efficacy in
patients have not been reported. We report the results of
the infusion of esmolol in 16 patients.
Methods
Study group (Table 1). Sixteen patients were studied
to determine the safety and efficacy of esmolol, an ultra-
short-acting beta-adrenergic blocking agent, in the treatment
of supraventricular tachyarrhythmia.
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Table 1. Summary of Patient Baseline Data and Response to Esmolol (ASL-8052) Infusion
Transient
Fall in
Systolic
Chronic or History Valvular Arrhythmia Arrhythmia BP < Conversion
Age (yr) Intermittent of Heart Amino- Causing Causing Symptomatic 100 to Sinus
Case Sex Rhythm Arrhythmia COPD Disease Digoxin phylline CHF Angina Improvement mm Hg Rhythm
I 76F MAT I +
2 92M Fib C + + + +
3 49F Fib C +
4 74M Fib C + +
5 73M Fib C + +
6 81F MAT I +
7 73M Fib I + + +
8 70M Flut I + + + + + + +
9 66M Flut C + + + +
10 66M Fib I AR + + + + +
II 55M AT I + +
12 33M Fib C MS + + + +
13 56M AT I + MR + + + + +
14 65F Fib C +
15 72F Fib C + +
16 26M Fib I
AR = aortic regurgitation; AT = atrial tachycardia; BP = blood pressure; C = chronic; CHF = congestive heart failure; COPD = chronic
obstructive pulmonary disease; F = female; Fib = atrial fibrillation; Flut = atrial flutter; I = intermittent; M = male; MAT = multifocal atrial
tachycardia; MR = mitral regurgitaion; MS = mitral stenosis; - = no; + = yes.
All patients were inpatients with supraventricular tachy-
arrhythmia at San Francisco General Hospital Medical
Center. They had an average ventricular response of greater
than 120 beats/min. There were II men (mean age 62 ±
19 years, range 26 to 92) and 5 women (mean age 67 ±
12years, range 49 to 81). Ten patients had atrial fibrillation
(including one associated with the Wolff-Parkinson-White
syndrome), two had atrial flutter, two had atrial tachycardia
andtwohadmultifocalatrial tachycardia.Eighthad a history
of chronicandeighta historyof intermittentsupraventricular
tachycardia; (in five of the latter the arrhythmia had acutely
recurred just before study).
At the time of the study, six patients had mild congestive
heart failure secondary to arrhythmia (Table I) that was
associated with chest pain in two. One patient had angina
secondary to atrial tachycardia. Six patients had mild chronic
obstructivepulmonarydisease; three werebeingtreatedwith
aminophylline at the time of the study. Thirteen were re-
ceiving digoxin at the time of the study. Three had valvular
heart disease (one had aortic insufficiency, one had mitral
stenosis and one had mitral insufficiency).
After giving informed, writtenconsent, each patient was
monitored electrocardiographically, and blood pressure re-
cordings were obtained for 30 minutes to establish with
certainty that the patient was in stable condition and that
the ventricular rate remained at more than 120 beats/min.
Treatment protocol. The study design was a double
blind, randomized, placebo-controlled trial of a parallel group
design. Two ampuls (Drug A and Drug B) were provided
for each patient by American Critical Care, McGaw Park,
Illinois. Esmolol was randomly assigned (50:50 chance) to
either Drug A or Drug B. The 10 ml ampul containedeither
1.0 g of esmolol dissolved in 10%propyleneglycol (USP),
10% alcohol (USP) and water for injection(USP), or 10 ml
of water for injection (USP). Each patient received Drug
A; if a therapeutic response was not observed, the patient
was crossed over to treatment with Drug B.
All patients were started on Drug A by continuous in-
fusion using an IMED model no. 928 volumetric infusion
pump. The drug was administered over six consecutive in-
fusion periods of 5 minutes each (maximum 30 minutes).
Each infusion period was composed of an initial I minute
bolus injectionof 500 p,g/kg followed by a 4 minuteinfusion
of 50, 100, 150,200,250 or a maximum of 300 p,g/kg per
min. If a response (that is, a sustained> 20% reduction in
the ventricular response or conversion to sinus rhythm) did
not occur during the stepwise infusion of Drug A, it was
stopped and Drug B was administered by the same method.
When a response was noted, stepwise increase in the
infusionrate was continued until the 200 p,g/kg per min rate
was achieved or systolic pressure fell below 100 mm Hg.
The infusion rate could then be increasedif a sustained 20%
reduction in ventricularrate had not been achievedprovided
that the systolic pressure was greater than 100 mm Hg. The
maximal rate to which the patient was titrated was continued
for an additional 30 minutes during maintenance infusion
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Figure 1. Case 8. Rhythm strips shown in conversion of atrial
flutter. A, Baseline atrial flutter before infusion. B, Atrial fibril-
lationduring 150 J-Lg/kg per min infusionof Drug A (esmololASL-
8052). C, Sinus rhythmduring maintenance infusionof 200 J-Lg/kg
per min. VR = ventricular rate. '
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a stepwise decrease in ventricular response was again ob-
served: 106.4 ± 17.2, 103.8 ± 17.0 and 99.5 ± 14.3
beats/min, respectively, after 100, 150 and 200 J,Lglkg. Three
representative rhythm strips from Patient 12 are shown in
Figure 3. Ventricular rate decreased from 149 to 113 beats/min
during the maximal infusion rate (250 jLg/kg per min); it
then increased to 129 beats/min after 30 minutes of follow-
up. The varied response to infusion noted among the patients
was not related to either the type of arrhythmia or the pres-
ence of digoxin.. The number of patients was too small to
analyze for the effect of digoxin.
Figure 4 shows the percent change in ventricular response
from the baseline (0.0%) of the 13 patients who did not
experience reversion to normal sinus rhythm. The mainte-
nance infusion rates (jLg/kg per min) were 50 (one patient),
200 (five patients), 250 (six patients) and 300 (one patient).
The end of the stepwise infusion is represented by time zero
followed by the 30 minute maintenance phase and the 60
minute follow-up phase. Continuous infusion over a 30 min-
ute period did not result in any significant change in heart
rate. After stopping the drug. a rapid increase in heart rate
was observed, with a response rate half-time of 15 to 20
minutes with a first order decay curve.
The subject who did not respond had the Wolff-Parkin-
son-White syndrome. During drug infusion. there was no
significant decrease or increase in the ventricular response.
A P I No
11 _
B Pattent No.
Date 8/11/82
! .' .. '. ..
C Patient No.
Results
phase and then stopped; the patient was monitored for 60
minutes thereafter. All ventricular rates were determined by
counting the number of ventricular responses on a 60 second
rhythm strip obtained during the last minute of each 5 minute
infusion period and during the last minute of each 10 minute
period during the maintenance and follow-up phases.
Blood pressure, respiratory rate and electrocardiogram
were closely monitored during the study. Physical exami-
nation and laboratory tests (chemistry, complete blood count
and urinalysis) were performed at the beginning and end of
the study. All responses during and after the infusion were
noted.
Statistical analysis. Data were analyzed using a paired
Student's t test or analysis of variance with repeated mea-
sures. In the Results section, data are presented as mean ±
I standard deviation.
The coding system was deciphered after completion of
the study protocol in these 16 patients. Ampul A contained
esmolol in seven cases, and ampul B contained esmolol in
nine cases. During stepwise infusion of the placebo in the
nine patients, no satisfactory response was observed; there-
fore, all nine were then crossed over to administration of
vial B. and a satisfactory response was subsequently noted
in eight.
Arrhythmia response. None of the eight chronic ar-
rhythmias experienced conversion to normal sinus rhythm
during esmolol ASL-8052 infusion compared with two (::15%)
of intermittent arrhythmias. No patient had any change in
rhythm during the placebo infusion. During infusionof esc
molol, one patient (Case 8) initially had atrial flutter that
converted transiently to atrial fibrillation during the 50 jLg/kg
per min infusion. Subsequently, normal sinus rhythm oc-
curred during the infusion of esmolol, 200 jLg/kg per min
(Fig. I).One patient (Case 10) experienced directconversion
from atrial fibrillation to normal sinus rhythm during the
200 jLg/kg per min infusion of esmolol. Both patients were
in normal sinus rhythm 12 hours after termination of the
study. The patient with the Wolff-Parkinson-White syn-
drome had a wide complex tachycardia with atrial fibrillation
at a response rate of 160 to 170 beats/min at the beginning
of the study. No change in the rate or pattern of the ar-
rhythmia was noted during the infusion of either Drug A or
Drug B,
Ventricular response. Esmolol produced a significant
dose-dependent decrease in the ventricular response in 15
patients (Fig. 2) (the one nonresponder is discussed sub-
sequently). The mean baseline ventricular rate of 133.2 ±
10.6 beats/min decreased to 111.0 ± 16.6 beats/min (prob-
ability [p] < 0.005) at the end of infusion of 50 jLg/kg per
min. Seven subjects received a maximal dose of 200, six
of 250 and one of 300 jLg/kg per min. In these 14 patients,
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Figure 2. Ventricular response to progressively higher infusion
rates of esmolol (ASL-8052) in 15 patients, A dose-related de-
crease in respollse occurred,
different (p < 0,05) at 78 ± 10 mm Hg. Seven patients
were given an infusion of 250 I-tg/kg per min with a systolic
pressure of 105 ± 19 and a diastolic pressure of 79 ± 14
mm Hg. One patient received a ma~imal dose of 300 I-tg/kg
per min, A dose-dependentchange can be seen from Figure
5. No cumulativeeffects on pressures were observed during
the maintenance phase, Thirty minutes after stopping the
infusion, no significantdifferencewas present from baseline
values: 131 ± 26 mm Hg for systolic pressure and 81 ±
II mm Hg for diastolic pressure.
Side effects. No subjective side effects were reported
by any patient. The six patients who had shortnessof breath
with mild congestive heart failure before infusion (Table I)
reported symptomatic improvementduring the maintenance
period. No patient reported dizziness, despite a decrease in
systolic blood pressure below 100 mm Hg in six patients
during the infusion (Table I). After discontinuation of the
study drug, all patients' blood pressures returned to baseline
values. At the end of the study, heart rate had returned to
prestudy levels, except in the two patients with conversion
to normal sinus rhythm. No significantphysical, chemical,
urologic or hematologic effects of drug infusion occurred
as judged by comparing the prestudy and poststudy evalu-
ations,' No changes were detected by physical examination
in the six patients with congestive heart failure who reported
symptomatic improvement. No wheezing was noted in any
of these patients during or after the infusion, Shortness of
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Figure 3. Case 12, Rhythm strips demonstrating ventricular re-
sponse to atrial fibrillation before, during 250 ILg/kg per min in-
fusion of esmolol (ASL-8052) and 30 millptes after stopping in-
fusion, HR = ventricular rate in beats/min.
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Blood pressure response. The systolic and diastolic
pressures are displayed in figure 5, Data from one patient
(Case 2) were not included because the maximal infusion
rate was only 50 ILg/kg per min, The rate of infusion was
not increased in, this patient above the level because the
initialdecrease in ventricular response was greater than 20%
and the systolic blood pressure decreased below 100 mm
Hg, All of the other subjects received at least 200 ILg/kg
per min; these data are shown in the infusion portion of
Figure 5, During this period, systolic pressure decreased
below 100 mm Hg ill 5 of the 14 patients, but returned to
the baseline state 30 minutes after cessation of the infusion,
However, six patients had no change in either systolic or
diastolic blood pressure, The reason for these differences
could not be determined, The two patients who converted
to normal sinus rhythm during the 200 ILg/kg per min in-
fusion were included in the analysis,
Baselinepressures in the 14patients were 135 ::t:: 22 mm
Hg (± standard deviation) for systolic and 86 ± 13 mm
Hg for diastolic. At 100 ILg/kg per min, systolic pressure
was significantly different (p < 0.01) at 125 ± 27 mm Hg.
At 150 I-tg/kg per min, diastolic pressure was significantly
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Figure4. Ventricular response during and
after maintenance infusion of esmolol
(ASL-8052) expressed as percent de-
crease from baseline (mean ± standard
error of themean). Thirteen patients who
responded to the infusion, but who did
not have conversion to normal sinus
rhythm, are represented. H.R. = ven-
tricular response inbeats/min; N = num-
berof patients.
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breathdid return in four of the patients with congestive heart
failure after completion of the study, but chest pain did not
return in the three patients who had had that complaint
before the study.
Discussion
This study demonstrates the effect of the new ultrashort-
acting beta-adrenergicblocking agent, esmolol. It is the first
in a family of new beta-blockers designed for use in the
hospital setting when blockade is required and a short du-
ration of action is desired. Our study was designed to de-
termine the efficacy of esmolol in the treatment of tachy-
arrhythmias of supraventricular origin and to evaluate its
safety over a short period of time.
Effects on ventricular response. Ventricular response
decreased in 15 of 16 patients in a predictable dose-depen-
dent manner; the patient with Wolff-Parkinson-White syn-
drome had no response. This patient had a wide QRS com-
plextachycardia at 160to 170beats/min withatrial fibrillation.
Drug infusion in this patient did not decrease or increase
the responserate. A possibleexplanationfor this observation
may be found in work with propranolol (4,5), where it had
no effect on the electrophysiologic properties of accessory
atrioventricular bypass tracts.
Duration of action. The observed short duration of ac-
tion was consistent with studies in animals and normal hu-
man volunteers (1-3,6). The rapid metabolism of the drug
160r
Figure 5. Blood pressure response to
stepwise infusion of esmolol (ASL-8052)
in 14 patients. (Case 2 was not included
because she only received a maximal in-
fusion of50 Mg/kg permin.) Maintenance
infusion rates (ug/kg per min) were 200
in seven patients, 250 in six and 300 in
one patient.
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is thoughtto be due to the actionof blood and tissueesterases
(7), The presence of cardiac pathology or congestive heart
failure, or both, did not prolong the duration of action of
esmolol in this study compared with the duration of effect
in normal human volunteers found in the study by Yacobi
et al. (3), Presumably, the presence of digoxin would en-
hance the responseto beta-adrenergic blockingagents; how-
ever, this was not readily apparent. Furthermore, the pres-
ence of aminophylline (a chronotrope), which might blunt
the response to infusion of esmolol, was not observed here
(Cases 2, 8 and 13). Both of these observations should be
studied further before any conclusions are reached,
Side effects. In this small group of patients, side effects
consisted entirely of a transient decrease in systolic and
diastolic blood pressures, but all affected patients were
asymptomatic, The exact mechanism of this was not evi-
dent. A decrease in heart rate might lead to hypotension as
well as a decrease in the inotropicstate of the heart, Murthy
et al. (8)observedin rabbitsa decrease in peripheral vascular
resistance that also could produce hypotension, An invasive
study will need to be performed to better understand the
hemodynamic effects on patients, Analysis of laboratory
results did not reveal any effects on blood and urine values
duringthe infusion,but somevalues, such as serumglutamic
oxaloacetic transaminase and alkaline phosphatase, may take
longer to increase. Although no laboratory changes were
noted when normal human volunteers received esmolol for
24 hours (2), the effects with prolonged infusion in acutely
ill patients are not yet known, The induction of broncho-
spasm by beta-adrenergic blockade is always a concern,
even when using agents that are cardioselective. Although
no patient with a history of bronchial asthma was studied,
six of our patients had chronic pulmonary disease, None of
these patients reported any change in symptoms, nor was
thereany appearanceof wheezing, This beta selectivitymay
prove clinically useful and has precipitated a study in our
hospital to determine the effects of esmolol on air flow in
asthmatic patients,
Clinical implications. We believe that esmolol is ef-
fective in reducing the ventricular response in patients with
a wide variety of chronic and acute supraventricular tachy-
arrhythmias, Esmolol appeared safe when administered for
a short period of time, though more studies need to be done
in this area, It may have no effect in patients with Wolff-
Parkinson-White syndrome when the atrioventricular node
is not part of the arrhythmic pathway. Furthermore, esmolol
may find clinical usefulness in settings in which rapid onset
and brief duration of beta-blocking action are needed.
The greatest use of ultrashort-acting beta adrenergic-
blockingagents will most likely be in patientswith ischemic
heart disease when the danger of producing heart failure
exists (9,10), Generally it is now known to what degree
ventricular function is dependent on intrinsic sympathetic
tone or to whatdegree beta adrenergic-blockade may produce
direct myocardial depression (10, II). When cardiac failure
does occur, it is moredesirableto withdraw the agentrapidly
rather than to counter the effects with beta-agonists. During
general anesthesia, esmolol may prove useful in treating
tachyarrhythmias without the problemof beta-blockade last-
ing through the entire procedure. Also esmolol may be use-
ful in treating patients with arrhythmias who have chronic
pulmonary disease,
We are grateful to Joani Newlands and Janet Greene for their work in the
preparation of the manuscript.
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